AI Enabled Precision Medicine

Brainomix, the award-winning University of Oxford spin-out, is making waves in the healthcare industry and medical imaging field with its AI-powered imaging biomarkers and software solutions for stroke care. Co-founded in 2010 by Michalis Papadakis, the company leverages AI to help physicians on a global scale to make more informed decisions when treating patients that have suffered from stroke. Brainomix has been successful in alleviating the burden that stroke places on healthcare systems, as one of the leading causes of disability and death worldwide. Backed by Boehringer Ingelheim, a renowned research-driven biopharmaceutical company, Brainomix has raised over $35 million in both private and public funding. Their primary focus is on stroke care and the company seeks to innovate in this field while simultaneously reducing healthcare costs.

The company has a vision to expand its innovative solution to other imaging areas. Brainomix has been recognized for its outstanding contribution to healthcare, winning the ICT award of the Academic Enterprise Awards, the only pan-European awards for spin-outs from universities. As of 2023, Brainomix has received FDA clearance, marking a significant milestone in the company's journey to help physicians save lives and improve the treatment pathways.

Brainomix has received approval for its groundbreaking work across multiple fronts, from investors to top-tier corporations and institutions, including Boehringer Ingelheim and the FDA.